132
Participants
Start Date
May 27, 2024
Primary Completion Date
October 8, 2027
Study Completion Date
December 8, 2027
HMPL-506
HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
RECRUITING
Xiangya Hospital of Central South University, Changsha
RECRUITING
First Affiliated Hospital of Chongqing Medical University, Chongqing
NOT_YET_RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
Nanfang Hospital, Southern Medical University, Guangzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
The Affiliated Hospital of Guizhou Medical University, Guiyang
RECRUITING
The First Affiliated Hospital, Zhejiang University, Hangzhou
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
Qilu Hospital of Shandong University, Jinan
RECRUITING
The First Affiliated Hospital with Nanjing Medical University, Nanjing
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
RECRUITING
Blood Diseases Hospital, Chinese Academy of medical Sciences, Tianjin
RECRUITING
Tianjin People's Hospital, Tianjin
RECRUITING
Wuhan Union Hospital of China, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
Hutchmed
INDUSTRY